ÕªÒª Ä¿µÄ£ºÃ÷È·Ï¥¹Ø½ÚÇ»×¢Éä²£Á§ËáÄÆÓëÍ´µã¼¤¹âÕÕÉä½áºÏÖÎÁÆÏ¥¹Ø½Ú¹Ç¹Ø½ÚÑ×µÄÁÙ´²ÁÆÐ§¡£·½·¨£º50Àý»¼ÕßËæ»ú·ÖΪ¹Û²ì×飨25Àý£©ºÍ¶ÔÕÕ×飨25Àý£©¡£È«²¿²¡Àý²ÉÓü¤¹âÖÎÁÆ£¬ÖÎÁÆÔÚ´Ë»ù´¡ÉϼӲ£Á§ËáÄÆ¹Ø½ÚÇ»ÄÚ×¢É䣬ÿÖÜ1´Î£¬5ÖÜΪ1ÁƳ̡£ÖÎÁÆÇ°¼°ÖÎÁÆ1ÁƳ̺ó½øÐÐÆÀ¹À¡£½á¹û£º¹Û²ì×é×ÜÓÐЧÂÊ100£¥£¬¶ÔÕÕ×éΪ76£¥£¬Á½×é±È½Ï²îÒìÏÔÖø£¨P<0.05£©¡£½áÂÛ£ºÏ¥¹Ø½ÚÇ»×¢Éä²£Á§ËáÄÆÓëÍ´µã¼¤¹âÕÕÉä½áºÏÖÎÁÆÏ¥¹Ø½ÚÑ×ÓÅÓÚµ¥´¿¼¤¹âÖÎÁÆ£¬×÷Óó־ÃÇÒ²»Ò׸´·¢£¬¸±×÷ÓÃÉÙ¡£
¹Ø¼ü´Ê Ï¥¹Ø½ÚÇ»£»²£Á§ËáÄÆ£»¼¤¹âÕÕÉ䣻ϥ¹Ø½Ú¹Ç¹Ø½ÚÑ×
Abstract Objective: To confirm clinical therapeutic effect in treatment of osteoarthritis in knee joint by laser treatment of trigger points associated with sodium hyaluronate injection in articular cavity. Methods: 50 patients with osteoarthritis in knee joint were randomly divided into treatment group(n=25) and control group(n=25).All patients were treated with laser, while the treatment group were added with sodium hyaluronate injection in articular cavity. Once a week, the course of both group were 5 weeks. The results before and after treatment were analyzed statistically. Results: The effect rate of treatments group is 100 percents, while the control group is 76 percents, the difference is significant (P<0.05).Conclusion: The effects of sodium hyaluronate injection in articular cavity associated with laser treatment of trigger points is better than laser treatments singly. Its effects are persistent, and not easy to recur ,short of side effects .
Key words: articular cavity, sodium hyaluronate, laser treatment, osteoarthritis in knee joint
Ï¥¹Ø½Ú¹ÇÐԹؽÚÑ×ÊÇÒ»ÖÖΣº¦ÈËÌ彡¿µ£¬ÑÏÖØÏÞÖÆ»¼ÕßÈÕ³£»î¶¯µÄÂýÐÔ³£¼û²¡£¬×Ô2002ÄêÒÔÀ´ÎÒÃÇÓ¦ÓÃÏ¥¹Ø½ÚÇ»ÄÚ×¢Éä²£Á§ËáÄÆ£¬Í¬Ê±Ó¦ÓÃHJZ-2EÐÍÖÇÄÜGAAIAS¼¤¹âÖÎÁÆÒÇÏ¥¹Ø½ÚÖÜΧʹµãÕÕÉ䣬ȡµÃÁ˷dz£ÂúÒâµÄÁÆÐ§£¬ÏÖ×ܽáÈçÏ¡£
• 1. ÁÙ´²×ÊÁÏ
1.1Ò»°ã×ÊÁÏ£º±¾×é50Àý£¬Ëæ»ú·ÖΪÁ½×飺¹Û²ì×é25Àý£¬Ë«Ï¥11Àý£¬µ¥Ï¥14Àý£¬ÄÐ13Àý£¬Å®12Àý£¬ÄêÁä40¡«75Ëꣻ¶ÔÕÕ×é25Àý£¬Ë«Ï¥13Àý£¬µ¥Ï¥12Àý£¬ÄÐ15Àý£¬Å®10Àý£¬ÄêÁä41¡«72Ëê¡£ÁÙ´²Ö¢×´ÎªÏ¥¹Ø½ÚÌÛÍ´£¬¹Ø½Ú»î¶¯ÓÐÏìÉù£¬²¿·Ö»¼ÕßÓÐÃ÷ÏÔ³¿½©ºÍ¹ÇÐÔ·Ê´ó¡£°éËæÖ¢×´ÓÐÏ¥¹Ø½ÚÄÚ·»òÏ¥¹Ø½ÚÍâ·±äÐΣ¬¹ÉËÄÍ·¼¡Î®Ëõ£¬¹Ø½Ú»ýÒº¡£XÏßÉãÆ¬¿É¼û¹Ø½Ú¼ä϶²»¶Ô³ÆÐÔÏÁÕºÍ/»ò¹Ø½ÚÃæÏ¹ÇÓ²»¯ºÍ/»ò÷Á¼äáÕ±ä¼âºÍ/»ò¹Ø½Ú±ßÔµ¹Ç׸Ðγɡ£Á½×黼ÕßµÄ Ö¸±êÎÞͳ¼ÆÑ§ÒâÒ壨P>0.05£©£¬¾ßÓпɱÈÐÔ¡£
1.2ÖÎÁÆ·½·¨£ºÁ½×é¾ùʹÓð뵼Ì弤¹âÆ÷£¨HJZ-2EÐÍ£¬²¨³¤810nm¹â°ßÖ±¾¶5mm£©Í´µãÕÕÉ䣬ÕÕÉ书ÂÊ200¡«350mw£¬Ã¿µãÕÕÉä7min£¬ÒÔÉÏÖÎÁÆÎªÃ¿Ìì1´Î£¬Ã¿ÖÜ5´Î¡£¹Û²ì×éÔÚ´Ë»ù´¡ÉϼÓÓò£Á§ËáÄÆ¹Ø½ÚÇ»ÄÚ×¢É䣬´©´ÌµãÑ¡ÔñÔÚ÷ƹÇÏ·½µÄ÷ÆÈÍ´øÄÚ²à»òÍâ²à¹Ø½Ú¼ä϶´©´Ì£¬½«Ï¥¹Ø½ÚÖÃÓÚ½ü90¶ÈÇüÇú룬³£¹æÏû¶¾ºóÖ±½Ó´©´Ì£¬Õë¼âÏòÏ¥¹Ø½ÚÖÐÉÏ·½Ð±ÐдÌÈë¹Ø½ÚÇ»£¬»Ø³éÎÞѪ£¬×¢ÉäÎÞ×èÁ¦£¬ÎÞÌÛÍ´Çé¿öÏÂÏò¹Ø½ÚÇ»ÄÚ×¢ÉäÊ©ÅæÌØ2ml£¨º¬²£Á§ËáÄÆ20mg£©£¬Ã¿ÖÜ×¢ÉäÒ»´Î£¬5ÖÜΪһÁƳ̣¬ÈôÓйؽڻýÒºÕߣ¬½«¹Ø½ÚÒº³é³öºóÔÙ×¢ÉäÊ©ÅæÌØ£¬×¢Éäºó»î¶¯Ï¥¹Ø½ÚÊý´Î£¬Ê¹Ò©Îï¾ùÔÈ·Ö²¼ÓÚÏ¥¹Ø½ÚÇ»ÄÚ¡£
1.3ÁÆÐ§ ¶¨£ºÁÙ´²Ö¢×´ÍêÈ«Ïûʧ£¬Ï¥¹Ø½Ú¹¦Äָܻ´Õý³££¬ÈÕ³£Éú»î»î¶¯ÎÞÕϰΪȬÓú£»ÁÙ´²Ö¢×´´ó²¿·ÖÏûʧ£¬Ï¥¹Ø½Ú¹¦ÄÜ»ù±¾»Ö¸´Õý³££¬ÈÕ³£Éú»î»î¶¯Ê±ÎÞÃ÷ÏÔÕϰΪÏÔЧ£»ÁÙ´²Ö¢×´²¿·ÖÏûʧ£¬Ï¥¹Ø½Ú¹¦ÄÜÓÐËù¸ÄÉÆ£¬ÈÕ³£Éú»î»î¶¯²¿·ÖÊÜÏÞΪÓÐЧ£»ÖÎÁÆÇ°ºóÎÞÃ÷ÏԱ仯ΪÎÞЧ¡£
• 2. ½á¹û ¹Û²ì×éÓÐЧÂÊ100£¥£¬¶ÔÕÕ×éÓÐЧÂÊ76£¥£¬Á½×éÁÆÐ§±È½Ï²îÒìÏÔÖø£¨P<0.05£©£¬Ïê¼û±í1¡£
|
×é±ð |
n |
ȬÓú |
ÏÔЧ |
ÓÐЧ |
ÎÞЧ |
P(X2)Öµ |
|
¹Û²ì×é |
25 |
16 |
4 |
5 |
0 |
<0.05 |
|
¶ÔÕÕ×é |
25 |
6 |
3 |
10 |
8 |
• 3. ÌÖÂÛ ¹ÇÐԹؽÚÑ×ÊÇÒ»ÖÖ·ÇÑ×ÐÔ¡¢ÂýÐÔ¡¢½øÐÐÐÔÇÖ·¸¿É»î¶¯¹Ø½ÚÌØ±ðÊǸºÖØ
¹Ø½ÚµÄ¼²²¡¡£²¡ÀíÑ§ÌØÕ÷ÊǹؽÚÈí¹Ç±äÐÔ¡¢¹Ø½ÚÄ¥ËðËùÖµĹؽڻúÄÜɥʧÓë¹Ø½Ú±ßÔµ¹Ç׸Ðγɡ£Ä¿Ç°²¡ÒòÉв»ÍêÈ«Çå³þ£¬ÓеÄר¼ÒÈÏΪËðÉË¡¢¹ý¶È¸ºÖØ¡¢ÉíÌå·ÊÅÖ¡¢¹Ø½Ú»ûÐμ°Ñ×Ö¢µÈÒòËØÓйأ¬ÁÙ´²ÉϱíÏÖΪϥ¹Ø½ÚÌÛÍ´¡¢Ö×ÕÍ¡¢»ûÐκ͹¦ÄÜÕϰ£¬ÓеÄר¼ÒÈÏΪ¶àÊýÊÇÓÉÓڹؽÚÖÜΧ¼¡ÈâÈÍ´ø³¤ÆÚÂýÐÔÀÍËð»òÒ»ÍâÉËÔì³ÉËðÉË£¬Ï¸°û»µËÀ£¬Ê¹µÃÈí×éÖ¯²»ÄÜÓÐЧµÄ±£»¤¹Ç×éÖ¯£¬²»ÄÜ´«µÝÓªÑøÎïÖÊ£¬×îºó³öÏÖ¾·ÂÎÐÔÂÎËõºÍÕ³Á¬£¬ÄÚ²¿Ô˶¯±»ÏÞÖÆ£¬ÆÆ»µÕý³£µÄ΢ѻ·£¬²Å³öÏÖ¹ÇÖÊÔöÉú²úÉú¶¯Ì¬Æ½ºâʧµ÷¡£
²£Á§ËáÄÆÊǹ¹³É¹Ø½ÚÈí¹ÇºÍ»¬ÒºµÄÖ÷Òª³É·Ö£¬ÎªÒ»ÖÖÏßÐÔÕ³¶àÌÇÎïÖÊ£¬Ö÷ÒªÓÉ»¬Ä¤Ï¸°ûºÍµ¥ºË¾ÞÊÉϸ°ûµÈºÏ³É¡£ÔڹؽÚÇ»ÄÚÆðÈ󻬡¢ÆÁÕϼ°»º³åÓ¦Á¦×÷Ó㬴Ӷø±£»¤Èí¹Ç£¬Î¬»¤Èí¹Ç»ùÖÊÍêÕû£¬ÆÁ±ÎÍ´¾õ¸ÐÊÜÆ÷£¬¸²¸ÇÓڹؽÚÈí¹Ç±íÃæµÄ²£Á§ËáÄÆ»¹¾ßÓзÖ×ÓɸºÍ±£»¤Ä¤µÄ×÷Ó㬽«¿ÉÈÜÐÔµ°°×µÈ×÷ÎªÓªÑøÒºÌṩ¸øÈí¹Ç×éÖ¯£¬¿É±ÜÃâÖ²¡Òò×Ó¶ÔÈí¹Ç×éÖ¯µÄÇÖÏ®¼°»î¶¯Ê±ÊÜËðÈí¹ÇÃæµÄ½øÒ»²½Ä¥ËðÆÆ»µ¡£²£Á§ËáÄÆÖÎÁÆÏ¥¹Ø½ÚÑ׿ÉÄÜÔÚÓÚ£ºÍ¸Ã÷ÖÊËáÄܲ¹³ä»òÌá¸ß»¬ÒºÖÐ͸Ã÷ÖÊËáÄÆº¬Á¿£¬Ôö¼Ó¹Ø½ÚÒºµÄÕ³³íÐÔºÍÈó»¬ÐÔ£¬×èÖ¹Ñ×ÐÔ½éÖÊ»òÈí¹Ç»ùÖʽµ½âøÓëÈí¹ÇµÄ½Ó´¥£¬·ÀÖ¹Èí¹Ç»ùÖʽøÒ»²½ÆÆ»µ£¬»¹¿ÉÒÖÖÆÈí¹ÇÆÆ»µ£¬¼ÓËÙÈí¹ÇºÏ³É´úл£¬Îȶ¨ºÍÐÞ¸´¹Ø½ÚÈí¹Ç£¬¼õÉÙ»¬Ä¤µÄͨ͸ÐÔ¼°¹Ø½ÚÄÚÉøÒº¡£
HJZ-2EÐÍÖÇÄÜGaAIAS¼¤¹â²¨³¤´¦ÓÚÈËÌå×éÖ¯ÎüÊÕ´°¿Ú£¬¶ÔÈËÌå×éÖ¯ÎüÓÐ
ЧÂʸߣ¬´©Í¸ÐԺ㨲¨³¤Îª830nmµÄ¼¤¹â´©Í¸ÈËÌå×éÖ¯×îÉî¿É´ï5¡«7cm£¬¼¤¹â¹¦ÂÊΪ100mwʱ£¬¿É´©Í¸¹Ç×éÖ¯3mm£¬ËðÉËãÐÖµ¿É´ï20w/cm²£¬Îªº¤Äʼ¤¹âµÄ20±¶£©£¬¼¤¹âÕÕÉäʱ²»»áÔì³É²»¿ÉÄæÐÔËðÉË£¬ÓкܸߵݲȫϵÊý¡£GaAIAS¼¤¹â²»½öÓйâµçЧӦ£¬»¹Óеç´Å¡¢¹â»¯¡¢¹âѹµÈ¶à·½ÃæµÄÉúÎïѧЧӦ£¬Í¨¹ý¶Ô¾Ö²¿»òÈ«ÉíµÄ×÷Ó㬾Éñ¾ÌåÒºµÄµ÷½Ú£¬¿É´ÙʹѪҺ¼°ÁܰÍÒºµÄÑ»·¼Ó¿ì£¬¼ÓËÙÖÂÍ´ÎïÖʼ°Ð³´úл²úÎïµÄÅųö£¬²¢¿É²úÉúÀàÂð·ÈÎïÖÊ£¬×÷ÓÃÓÚ²¡±ä²¿Î»£¬ÓÐÏûÑ×ֹʹ¡¢ÐÞ¸´ËðÉË×éÖ¯¡¢Ìá¸ßÃâÒß¹¦ÄܵÈ×÷ÓÃ[8]¡£HJZ-2EÐÍÖÇÄÜGaAIAS¼¤¹â±ãÓÚÕÕÉ䣬¿ÉÌæ´ú¾Ö²¿Í´µã·â±ÕÖÎÁÆ¡£ÌرðÊÊÓ¦ÓÚÄêÀÏÌåÈõ°éÓÐÉúÃüÆ÷¹Ù¼²²¡µÄ»¼Õߣ¬ÎÞ³¤ÆÚʹÓþֲ¿Í´µã·â±ÕÒò×¢ÉäÌí¼ÓÉÙÁ¿Æ¤Öʼ¤ËؼÓÖØÌÇÄò²¡£¬´Ù½ø¹ÇÖÊÊèËÉÖ¢µÄ²»Á¼Ó°Ïì¡£
±¾×鲡ÀýÁÙ´²½á¹û±íÃ÷£º²£Á§ËáÄÆÏ¥¹Ø½Ú×¢ÉäÓëÏ¥¹Ø½ÚÖÜΧʹµãHJZ-2EÐÍ
ÖÇÄÜGaAIAS¼¤¹âÕÕÉäÏàÅäºÏ£¬ÖÎÁÆÏ¥¹Ø½Ú¹Ç¹Ø½ÚÑ×¾ßÓзdz£ºÃµÄÁÆÐ§¡£
²Î¿¼ÎÄÏ×
[1]»ÆÇǶ«µÈ£®Éú³¤ÒÖËØ¹Ø½ÚÇ»ÄÚ×¢ÉäÖÎÁÆÏ¥¹Ø½Ú¹ÇÐԹؽÚÑ×µÄÁÆÐ§¹Û²ì£®¹ã¶«Ò½Ñ§£®2006£¬01£®8-9¡£
[2]κ¼Ì¶«£®Ï¥¹Ø½Ú¹ÇÐԹؽÚÑ×µÄ×ÛºÏÖÎÁÆ[J]£®Öйú³§¿óҽѧ,2005,18(4)£º329-331¡£
[3]Ò¦¸£¶«£¬ÕžüÈð£®Ï¥¹Ø½Ú¹ÇÐԹؽÚÑ×ÖÐÎ÷Ò½ÖÎÁÆÖ®ÎÒ¼û [J]£®ÉÂÎ÷ÖÐÒ½£¬2005£¬269(1)£º61-62£®
[4]£»ÁèÅæÑ§£®Í¸Ã÷ÖÊËá[M]£®±±¾©£ºÖйúÇṤҵ³ö°æÉç,2003£º137-141£®
[5]DuJR,JiangY,ZhangYM,etal.Vascularendothelialgrowthfactorandmicro vasculardensityinesophagealandgastriccarcinomas[J].WorldJGastroenterol,2003,9(7):1604-1606.
[6]UchidaS,ShimadaY,WatanabeG,etal.Inoesophagealsquamouscellcarcinomavascularendothelialgrowthfactorisassociatedwithp53mutation,advancedstageandpoorprognosis[J].BrJCancer,1998,77(10):1704-1709.
[7]JapaneseEsophagealOncologyGroup.Acomparisonofchemotherapyandradiotherapyasadjuvanttreatmenttosurgeryforesophagealcarcinoma[J].Chest,1993,104(1):203-207.
[8]Ñî»ÝÇÙ£®¼¤¹âѨλµãÉäÁÆ·¨¶ÔÍ´·ç¼±ÐÔÆÚµÄÁÆÐ§¹Û²ì£®ÖйúÖÐÒ½¹ÇÉË¿ÆÔÓÖ¾,2006,14(1)£º19-20¡£
TAG: Ï¥¹Ø½ÚÇ» ²£Á§ËáÄÆ ¼¤¹âÕÕÉä Ï¥¹Ø½Ú¹Ç¹Ø½ÚÑ×






